AIM
VTGN icon

Acrospire Investment Management’s VistaGen Therapeutics VTGN Stock Holding History

Acrospire Investment Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed – – 2561
2017
Q1 		$0 Buy
+3
New +$243 ﹤0.01% 2521

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's VTGN Position: Q2 2017 in Review

Acrospire Investment Management sold out of VistaGen Therapeutics (VTGN) in Q2 2017, closing a stake of 3 shares.

Acrospire Investment Management first reported a position in VTGN in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 14 funds tracked by Wall St. Rank hold VTGN as of Q2 2017.

  • Acrospire Investment Management reported no remaining VistaGen Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3 VistaGen Therapeutics shares in Q2 2017.
  • Acrospire Investment Management first reported a position in VistaGen Therapeutics in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's VistaGen Therapeutics position peaked at $0 in Q1 2017.
  • 14 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.